Clinical Trials Industry News More
-
Bibliography Demonstrates Applications Of UV Area Imaging
6/26/2009
Paraytec Ltd., the developer of the world's first quantitative UV area imaging system, has announced a major expansion of their online applications bibliography and technical downloads section.
-
New BioFlux 1000 Workstation Enables High-Throughput, High-Content Cellular Assays
6/23/2009
Fluxion Biosciences introduces the BioFlux 1000 Workstation – a cell analysis system that integrates the company’s Well Plate Microfluidic technology with automated microscopy for high-throughput shear flow assays.
-
A Highly Reproducible Cell Migration Screening Assay
6/22/2009
amsbio has announced a new generation of novel two-dimensional cell-based assay kits developed for reproducibly screening test compounds that may stimulate or inhibit adherent cell migration.
-
Nanocrystals Reveal Activity Within Cells
6/17/2009
Researchers at the U.S. Department of Energy’s (DOE) Lawrence Berkeley National Laboratory have created bright, stable and bio-friendly nanocrystals that act as individual investigators of activity within a cell. These ideal light emitting probes represent a significant step in scrutinizing the behaviors of proteins and other components in complex systems such as a living cell.
-
Direct Elemental (CHN) Analysis Of Environmental Filter Samples
6/12/2009
Exeter Analytical Inc. has published an application note describing direct determination of total Carbon, Hydrogen and Nitrogen in environmental air and water filter samples
-
FDA Forms Transparency Task Force
6/4/2009
The U.S. Food and Drug Administration (FDA) recently announced the formation of a task force to develop recommendations for enhancing the transparency of the agency’s operations and decision-making process.
-
Cornerstone Pharmaceuticals Initiates Phase I/II Combination Therapy Clinical Trial Of CPI-613 For Treatment Of Pancreatic Cancer
5/28/2009
Cornerstone Pharmaceuticals, Inc., a privately-held pharmaceutical company, announced today that it has begun a phase I/II clinical trial of CPI-613, the initial candidate to emerge from the company's Altered Energy Metabolism Directed technology platform.
-
Johnson & Johnson Announces Definitive Agreement To Acquire Cougar Biotechnology, Inc.
5/25/2009
Johnson & Johnson and Cougar Biotechnology, Inc., a development stage biopharmaceutical company with a specific focus on oncology, recently announced a definitive agreement whereby Cougar Biotechnology will be acquired for approximately $1.0B in a cash tender offer.
-
Breakthrough In Radiotherapy Promises Targeted Cancer Treatment
5/20/2009
Current radiation therapy treatment damages a patient’s healthy tissue as well as eradicating the tumour it is intended to destroy, making the treatment especially invasive and often causing nasty side effects.
-
Flow Of Potassium Into Cells Implicated In Schizophrenia Blocking Errant Protein Could Stem Runaway Brain Activity In Psychosis
5/6/2009
A study on schizophrenia has implicated machinery that maintains the flow of potassium in cells and revealed a potential molecular target for new treatments.
This website uses cookies to ensure you get the best experience on our website. Learn more